Abstract |
Based on improved survival from the addition of PD-L1 inhibitors in phase III trials, the combination of immunotherapy and platinum-doublet chemotherapy has become the new standard treatment for extended-stage small-cell lung cancer (ES-SCLC). Furthermore, the antiangiogenetic agent bevacizumab showed a longer progression-free survival by targeting VEGF that has pleiotropic effects, including immunosuppressive ones. We, therefore, hypothesized that targeting angiogenesis would improve the efficacy of chemoimmunotherapy. The CeLEBrATE trial is an open-label, multicenter, phase II study designed to assess the efficacy and safety of the combination of carboplatin and etoposide plus bevacizumab and atezolizumab in treatment-naive patients with ES-SCLC. The primary end point is overall survival rate at 1 year, while secondary end points include overall response rate, progression-free survival and toxicity.
|
Authors | Elisa Andrini, Giuseppe Lamberti, Francesca Mazzoni, Ferdinando Riccardi, Andrea Bonetti, Alessandro Follador, Fabrizio Artioli, Carlo Genova, Fausto Barbieri, Antonio Frassoldati, Matteo Brighenti, Ida Colantonio, Giulia Pasello, Corrado Ficorella, Saverio Cinieri, Marcello Tiseo, Francesco Gelsomino, Michele Tognetto, Karim Rihawi, Andrea Ardizzoni |
Journal | Future oncology (London, England)
(Future Oncol)
Vol. 18
Issue 7
Pg. 771-779
(Mar 2022)
ISSN: 1744-8301 [Electronic] England |
PMID | 35068173
(Publication Type: Clinical Trial Protocol, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- atezolizumab
- Bevacizumab
- Carboplatin
- Etoposide
|
Topics |
- Humans
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bevacizumab
(administration & dosage)
- Carboplatin
(administration & dosage)
- Clinical Trials, Phase II as Topic
- Etoposide
(administration & dosage)
- Lung Neoplasms
(drug therapy, pathology)
- Multicenter Studies as Topic
- Research Design
- Small Cell Lung Carcinoma
(drug therapy, pathology)
|